Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC

Sevabertinib shows manageable diarrhoea without impacting efficacy in HER2-mutant lung cancer

Subcutaneous amivantamab plus lazertinib shows durable responses in EGFR-mutant advanced lung cancer

EAU 2026: Updates in NMIBC

Microplastics found at higher levels in prostate cancer tissue compared to benign tissue

Durvalumab plus tremelimumab temporarily reduces QoL in resected renal cell carcinoma patients

Patients with non-metastatic HSPC prefer ARPI-based therapy over androgen deprivation alone

ASCO GU 2026: Updates in renal cancer

ASCO GU 2026: Updates in metastatic prostate cancer

ASCO GU 2026: Updates in localised prostate cancer

Post-orchiectomy miR-371 predicts recurrence in clinical stage I testicular germ cell tumours during active surveillance

Evaluation and definition of response and progression from trials to clinical practice